Allarity Therapeutics Inc. Common Stock (ALLR)

About ALLR

Allarity Therapeutics, Inc., a clinical-stage precision medicine pharmaceutical company, focuses on developing anti-cancer therapeutics for patients with unmet medical needs in Denmark and the United States. The company develops drugs for the personalized treatment of cancer using drug-specific companion diagnostics generated by its proprietary drug response predictor (DRP) technology. Its lead drug candidate is sten…

Sector

Health Care

Industry

Biotechnology: Pharmaceutical Preparations

Employees

7

Website

allarity.com/

Fundamentals

1-day range

$1.35$1.46

Market cap

$19.64M

P/E (trailing)

—

P/E (forward)

-1.45

EPS (trailing)

$-0.72

Dividend yield

—

Beta

0.60

Avg. volume

114.9K

Forecasts

1 analyst ratings

Allarity Therapeutics Inc. Common Stock Competitors

Chosen by industry and closest market cap.

• ALLR

  Allarity Therapeutics Inc. Common Stock

  $1.41

  ▲ 2.17%
  Market cap $19.64MP/E —
  $0.769$2.06
• PLRZ

  Polyrizon Ltd. Ordinary Shares

  $12.7

  ▼ 0.78%
  Market cap $19.82MP/E —
  $2.88$18.2
• DARE

  Dare Bioscience Inc. Common Stock

  $0.7437

  ▲ 0.64%
  Market cap $19.17MP/E —
  $0.72$3.78
• MRKR

  Marker Therapeutics Inc. Common Stock

  $1.37

  ▼ 7.12%
  Market cap $20.34MP/E —
  $0.8099$2.46
• SKYE

  Skye Bioscience Inc. Common Stock

  $1.81

  ▼ 7.18%
  Market cap $20.53MP/E —
  $1.84$39.92
• NCEL

  NewcelX Ltd. Ordinary Shares

  $3.19

  ▼ 6.73%
  Market cap $18.41MP/E —
  $1.83$24.6
• NEUP

  Neuphoria Therapeutics Inc. Common Stock

  $3.82

  ▲ 1.33%
  Market cap $21.24MP/E —
  $3.19$21.4

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• Allarity Therapeutics Q2 EPS $(0.21) Beats $(0.25) Estimate
  benzinga · 8/14/2026
• Allarity Therapeutics Q2 EPS $(0.21) Beats $(0.25) Estimate
  Benzinga · 8/14/2026

Institutional Ownership

March 31, 2026

Total shares held

875.7K

Total value held

$954.5K

Institutional holders

13